JP2008528621A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008528621A5 JP2008528621A5 JP2007553304A JP2007553304A JP2008528621A5 JP 2008528621 A5 JP2008528621 A5 JP 2008528621A5 JP 2007553304 A JP2007553304 A JP 2007553304A JP 2007553304 A JP2007553304 A JP 2007553304A JP 2008528621 A5 JP2008528621 A5 JP 2008528621A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- administered
- des
- weeks
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64749605P | 2005-01-27 | 2005-01-27 | |
| PCT/US2006/003116 WO2006081510A2 (en) | 2005-01-27 | 2006-01-27 | Methods for treating renal cell carcinoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011266809A Division JP2012046552A (ja) | 2005-01-27 | 2011-12-06 | 腎細胞ガンを処置するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008528621A JP2008528621A (ja) | 2008-07-31 |
| JP2008528621A5 true JP2008528621A5 (https=) | 2009-01-29 |
Family
ID=36741121
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007553304A Pending JP2008528621A (ja) | 2005-01-27 | 2006-01-27 | 腎細胞ガンを処置するための方法 |
| JP2011266809A Pending JP2012046552A (ja) | 2005-01-27 | 2011-12-06 | 腎細胞ガンを処置するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011266809A Pending JP2012046552A (ja) | 2005-01-27 | 2011-12-06 | 腎細胞ガンを処置するための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20070014765A1 (https=) |
| EP (1) | EP1846020B1 (https=) |
| JP (2) | JP2008528621A (https=) |
| KR (1) | KR20070102576A (https=) |
| CN (1) | CN101132809A (https=) |
| AU (1) | AU2006207987B2 (https=) |
| BR (1) | BRPI0606774A2 (https=) |
| CA (1) | CA2595959A1 (https=) |
| ES (1) | ES2432141T3 (https=) |
| IL (1) | IL184865A (https=) |
| MX (1) | MX2007009012A (https=) |
| RU (1) | RU2404795C2 (https=) |
| WO (1) | WO2006081510A2 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110243851A1 (en) | 2008-12-11 | 2011-10-06 | Agency For Science, Technology And Research | Glucose-peg conjugates for reducing glucose transport into a cell |
| US20150299255A1 (en) * | 2010-11-01 | 2015-10-22 | Susavion Biosciences, Inc. | Compositions and methods for modulating innate and adaptive immune systems |
| CA2860170C (en) | 2010-12-22 | 2022-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| DK2683395T3 (en) * | 2011-03-11 | 2018-11-19 | Hopitaux Paris Assist Publique | USE OF LOW DOSAGE IL-2 FOR TREATMENT OF TYPE 1 DIABETES |
| BR112013023151A2 (pt) * | 2011-03-11 | 2020-09-15 | Assistance Publique - Hôpitaux De Paris | interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado |
| CN105722860A (zh) | 2013-09-24 | 2016-06-29 | 梅迪塞纳医疗股份有限公司 | 白介素-2融合蛋白及其应用 |
| WO2015164815A1 (en) | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| AU2015301936B2 (en) | 2014-08-11 | 2019-03-07 | Delinia, Inc. | Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases |
| US10350260B2 (en) * | 2015-04-27 | 2019-07-16 | Susavion Biosciences, Inc. | Compositions and methods for treating cancer and persistent viral infections |
| JP6740250B2 (ja) * | 2015-04-27 | 2020-08-12 | スサヴィオン バイオサイエンシーズ インコーポレイテッド | がんおよび持続性ウイルス感染を処置するための組成物および方法 |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| EP3538548A4 (en) | 2016-11-08 | 2020-08-19 | Delinia, Inc. | IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
| CU24483B1 (es) * | 2016-11-15 | 2020-04-02 | Ct Inmunologia Molecular | Método para incrementar los niveles de secreción de la interleucina-2 |
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| MY206158A (en) | 2017-05-24 | 2024-12-02 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| CN111201035A (zh) | 2017-06-19 | 2020-05-26 | 梅迪塞纳医疗股份有限公司 | Il-2超激动剂、激动剂及其融合体的用途和方法 |
| JP7325341B2 (ja) | 2017-07-11 | 2023-08-14 | シンソークス，インク． | 非天然ヌクレオチドの組み込み及びその方法 |
| KR20240141853A (ko) | 2017-08-03 | 2024-09-27 | 신톡스, 인크. | 자가면역 질환의 치료를 위한 사이토카인 접합체 |
| KR102777151B1 (ko) * | 2017-11-21 | 2025-03-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 인터루킨-2의 부분 효능제 |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| SG11202102930YA (en) | 2018-11-08 | 2021-04-29 | Synthorx Inc | Interleukin 10 conjugates and uses thereof |
| EP3923974A4 (en) | 2019-02-06 | 2023-02-08 | Synthorx, Inc. | IL-2 CONJUGATES AND METHODS OF USE THEREOF |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| BR112021023345A2 (pt) | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Imunotolerância com alvo em madcam |
| EP4017540A1 (en) | 2019-08-23 | 2022-06-29 | Synthorx, Inc. | Il-15 conjugates and uses thereof |
| US12234271B2 (en) | 2019-09-10 | 2025-02-25 | Synthorx, Inc. | Il-2 conjugates and methods of use to treat autoimmune diseases |
| WO2021127487A2 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| US11633488B2 (en) | 2020-01-10 | 2023-04-25 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
| EP4107187A4 (en) | 2020-02-21 | 2024-07-03 | Pandion Operations, Inc. | TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR |
| TW202317623A (zh) | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | 基於il2之治療劑及其使用方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4752585A (en) * | 1985-12-17 | 1988-06-21 | Cetus Corporation | Oxidation-resistant muteins |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4931543A (en) | 1987-05-11 | 1990-06-05 | Cetus Corporation | Process for recovering microbially produced interleukin-2 |
| US5830452A (en) * | 1990-11-20 | 1998-11-03 | Chiron Corporation | Method for enhancing the anti-tumor therapeutic index of interleukin-2 |
| ES2264145T3 (es) * | 1995-11-30 | 2006-12-16 | The Board Of Regents, The University Of Texas System | Metodos y composiciones para el tratamiento de cancer. |
| US7632496B2 (en) * | 2002-07-01 | 2009-12-15 | Wilex Ag | Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas |
-
2006
- 2006-01-27 JP JP2007553304A patent/JP2008528621A/ja active Pending
- 2006-01-27 EP EP06719806.9A patent/EP1846020B1/en not_active Expired - Lifetime
- 2006-01-27 BR BRPI0606774-3A patent/BRPI0606774A2/pt not_active Application Discontinuation
- 2006-01-27 CA CA002595959A patent/CA2595959A1/en not_active Abandoned
- 2006-01-27 MX MX2007009012A patent/MX2007009012A/es active IP Right Grant
- 2006-01-27 ES ES06719806T patent/ES2432141T3/es not_active Expired - Lifetime
- 2006-01-27 AU AU2006207987A patent/AU2006207987B2/en not_active Ceased
- 2006-01-27 KR KR1020077019556A patent/KR20070102576A/ko not_active Ceased
- 2006-01-27 US US11/342,243 patent/US20070014765A1/en not_active Abandoned
- 2006-01-27 RU RU2007132125/14A patent/RU2404795C2/ru not_active IP Right Cessation
- 2006-01-27 WO PCT/US2006/003116 patent/WO2006081510A2/en not_active Ceased
- 2006-01-27 CN CNA2006800067217A patent/CN101132809A/zh active Pending
-
2007
- 2007-07-26 IL IL184865A patent/IL184865A/en active IP Right Grant
-
2009
- 2009-07-28 US US12/460,991 patent/US8012465B2/en not_active Expired - Fee Related
-
2011
- 2011-12-06 JP JP2011266809A patent/JP2012046552A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008528621A5 (https=) | ||
| RU2007132125A (ru) | Способы лечения почечноклеточной карциномы | |
| Yang et al. | The use of polyethylene glycol‐modified interleukin‐2 (PEG‐IL‐2) in the treatment of patients with metastatic renal cell carcinoma and melanoma | |
| ES2380107T3 (es) | Combinación de inmunogenoterapia y quimioterapia para el tratamiento del cáncer y enfermedades hiperproliferativas | |
| Christmas et al. | Effect of Interferon-α2a Malignant Mesothelioma | |
| JP2004524278A5 (https=) | ||
| JP2013533858A5 (https=) | ||
| Hande et al. | Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small cell lung cancer | |
| RU2008138560A (ru) | Улучшенные способы лечения опухолей | |
| Cascinu et al. | A phase I–II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) | |
| JP3465824B2 (ja) | 腫瘍治療用医薬組成物 | |
| Lissoni et al. | Prognostic Factors of the Clinical Response to Subcutaneous Immunotherapy with lnterleukin-2 Alone in Patients with Metastatic Renal Cell Carcinoma | |
| Pasricha et al. | Treatment of pemphigus with cyclophosphamide | |
| Gailani et al. | Comparison of treatment of metastatic gastrointestinal cancer with 5‐fluorouracil (5‐FU) to a combination of 5‐FU with cytosine arabinoside | |
| JP2006514681A5 (https=) | ||
| Johnson et al. | A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas | |
| Yamao et al. | Phase I–II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer | |
| JP2009539916A5 (https=) | ||
| Clark et al. | Two randomised phase II trials of intermittent intravenous versus subcutaneous alpha-2 interferon alone (trial 1) and in combination with 5-fluorouracil (trial 2) in advanced colorectal cancer | |
| JP3712914B2 (ja) | 腎細胞ガン処置 | |
| Chaplin et al. | Plegridy for the treatment of RRMS in adults | |
| JP2001288110A5 (https=) | ||
| JP2005529152A5 (https=) | ||
| Atzpodien et al. | Treatment of metastatic renal cell cancer patients with recombinant subcutaneous human interleukin-2 and interferon-α | |
| HK1045119A1 (zh) | 用於治療癌症的放射性順鉑 |